Trajan and IQVIA Highlight How Blood Microsampling Can Support More Patient-Centric Clinical Trials

In a recent live discussion, Trajan Scientific and Medical and IQVIA Laboratories examined how blood microsampling is reshaping clinical trial design to enhance patient convenience, operational flexibility, and access.

The webinar highlighted that microsampling enables home and self-collection, supports decentralized study models, and reduces burdens for both patients and sites.

The discussion also spotlighted its applicability in PK, PD, safety testing, biomarker analysis, genomics, and studies involving pediatric, rare disease, elderly, and mobility-restricted populations.

A featured case study demonstrated how dried blood microsampling supported a pediatric rare disease trial requiring frequent biomarker measurements. The approach enabled patient self-collection, showed strong correlation with plasma testing, maintained stability at room temperature and under stress, and accelerated biomarker turnaround.

Speakers noted that retraining improved sample quality to 100%, emphasizing the importance of clear education and support for successful implementation.

A second case study examined an epilepsy trial with time-sensitive post-dose sampling. IQVIA explained that self-collection with dried blood sampling offered patients greater flexibility than hospital stays or on-call home phlebotomy, while also reducing logistical complexity and, in some cases, cost.

Key considerations Included:

• Protocol design

• Patient population fit

• Sample type selection

• Bridging studies

• Shipping strategy

• Regulatory alignment

• And site and patient training

Presenters emphasized that protocol design, analytical validation, operational logistics, and training should be addressed before study execution to maximize the benefits of microsampling in clinical trials. #LINK#